424 related articles for article (PubMed ID: 29298625)
1. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
7. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
[TBL] [Abstract][Full Text] [Related]
8. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
9. Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
Rosa María RN; Laura RL; Ángeles PB; Laura LB
Platelets; 2020; 31(3):403-406. PubMed ID: 31116059
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Kuter DJ; Arnold DM; Rodeghiero F; Janssens A; Selleslag D; Bird R; Newland A; Mayer J; Wang K; Olie R
Am J Hematol; 2020 Jun; 95(6):643-651. PubMed ID: 32129511
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
14. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
Janssens A; Tarantino M; Bird RJ; Mazzucconi MG; Boccia RV; Fernández MF; Kozak T; Steurer M; Boekhorst Pt; Dillingham K; Kreuzbauer G; Woodard P
Acta Haematol; 2015; 134(4):215-28. PubMed ID: 26066765
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
17. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center.
Wong A; Ahuja T; Cirrone F; Xiang E
J Oncol Pharm Pract; 2024 Mar; 30(2):246-250. PubMed ID: 37132025
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
20. Use of romiplostim for primary immune thrombocytopenia in children.
Escudero Vilaplana V; Aragonés JH; Fernández-Llamazares CM; Bieler CB; Rodríguez SM; Sáez MS
Pediatr Hematol Oncol; 2012 Mar; 29(2):197-205. PubMed ID: 22376020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]